Q3 2023 Earnings Estimate for Humana Inc. (NYSE:HUM) Issued By Oppenheimer
Humana Inc. (NYSE:HUM – Get Rating) – Analysts at Oppenheimer dropped their Q3 2023 EPS estimates for Humana in a research report issued to clients and investors on Wednesday, February 1st. Oppenh
Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)
Humana Inc. Stock Falls Friday, Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Humana Inc. (HUM) slipped 2.70% to $476.57 Friday, on what proved to be an all-around poor
Humana Is Maintained at Overweight by Stephens & Co.
Humana Price Target Cut to $590.00/Share From $625.00 by Stephens & Co.
Stephens & Co. Maintains Overweight on Humana, Lowers Price Target to $590
Stephens & Co. analyst Scott Fidel maintains Humana with a Overweight and lowers the price target from $625 to $590.
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)
Humana Full Year 2022 Earnings: EPS Misses Expectations
Humana (NYSE:HUM) Shares Gap Down After Analyst Downgrade
Humana Inc. (NYSE:HUM – Get Rating) gapped down before the market opened on Thursday after TheStreet downgraded the stock from a b rating to a c+ rating. The stock had previously closed at $513.28, b
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Humana (HUM)
No Stock Yet